Updated:
Terumo
Terumo was founded in 1921 by a group of physicians and engineers who imported clinical thermometers into Japan, creating the country's first domestic medical...
Terumo
Terumo was founded in 1921 by a group of physicians and engineers who imported clinical thermometers into Japan, creating the country's first domestic medical device supply chain. President and CEO Shinjiro Sato now leads a publicly traded entity whose corporate venture activities flow through a centralized balance-sheet strategy rather than a ring-fenced fund structure. The firm's investment identity is inseparable from its manufacturing footprint — it operates in over 160 countries and derives roughly 70% of revenue outside Japan, giving its venture and M&A teams a built-in distribution network for portfolio technologies. Terumo allocates corporate venture capital and strategic M&A across three divisions: cardiovascular, medical care solutions, and blood-and-cell technologies. Its deal posture favors late-stage minority investments and full bolt-on acquisitions of companies whose devices can integrate directly into its existing hospital sales channels. Notable investments include MicroVention, the US-based neurovascular device company acquired in 2006 and now a primary growth driver, and the 2017 acquisition of Bolton Medical for its aortic stent-graft platform. In 2021 Terumo acquired HealthSense, a digital health platform for remote patient monitoring, signaling a push beyond pure hardware into connected therapeutic devices. The firm co-invests alongside specialist medtech VCs but typically negotiates exclusive commercial rights in Asia-Pacific markets as part of term structures. The corporate venture group operates out of Tokyo with additional investment professionals stationed in US and European commercial offices to source deals in the interventional cardiology, neuro-interventional, and transfusion-medicine corridors. The firm employs over 30,000 people globally, with the venture and business development team forming a lean unit within the CEO's strategy function. In March 2024, Terumo announced a strategic reorganization consolidating its digital health and device connectivity units under a single division, signaling an intention to accelerate investments in software-enabled hardware platforms across its existing hospital-installed base. Terumo's structural differentiator is distribution-channel co-option: the firm can acquire a niche device company, push its product through an existing sales force that already serves the same hospital call points, and achieve margin expansion without building a new commercial footprint from scratch. Few cardiovascular-device acquirers can offer a portfolio company simultaneous access to Japan's regulated hospital procurement system and a direct sales presence in 160 countries, giving Terumo's corporate-venture arm a pricing advantage in competitive processes that independent medtech VCs cannot replicate.
General information
Firm type
Corporate Investor
Year founded
1921
AUM
Undisclosed
Location
Region
Asia
Country
Japan
City
Tokyo
Corporate office
Tokyo, Japan
Principals
Takayoshi Mimura
Chairman
Shinjiro Sato
President & CEO
Sector focus
Frequently asked questions
How is Terumo's venture activity different from an independent medtech VC?
Terumo invests off its own corporate balance sheet, using strategic minority stakes and full acquisitions to acquire technologies that can be routed through its existing hospital sales channels. Independent VCs must build commercial pathways from scratch; Terumo can offer portfolio companies immediate distribution into 160 countries and preferential access to Japan's regulated procurement system. The firm typically negotiates exclusive Asia-Pacific commercial rights alongside any equity participation.
Who makes investment decisions at Terumo?
The corporate venture and business development team sits within the CEO's strategy function under President Shinjiro Sato. Deal recommendations flow up through a combination of divisional general managers and a central investment committee, with final authority resting with Sato and the board for acquisitions above a materiality threshold. The firm has not disclosed the exact composition of its investment committee.
Which therapeutic areas does Terumo invest in?
Terumo's investment focus mirrors its three operating divisions: cardiovascular interventions including neurovascular and aortic stent-grafts, medical care solutions covering IV therapy and drug-delivery devices, and blood-and-cell technologies for transfusion medicine and apheresis. The 2021 acquisition of HealthSense marked an expansion into digital health and remote patient monitoring as a fourth investment corridor.
Does Terumo co-invest alongside external venture firms?
Yes. Terumo co-invests alongside specialist medtech VCs in late-stage rounds where the portfolio company's device can benefit from its Asia-Pacific commercial channel. The firm does not operate a formal LP program into external fund managers — all investments are direct and tied to a strategic-use case within its existing hospital call-point network.
How large is Terumo's venture and M&A deployment capacity?
Terumo does not disclose a dedicated venture or M&A allocation amount. As a publicly traded company with over ¥1 trillion in annual revenue and a market capitalization exceeding ¥4 trillion, the firm has balance-sheet capacity to execute acquisitions at scale — its past transactions include the multi-billion-dollar acquisition of MicroVention. Actual annual deployment varies based on pipeline and strategic priorities.
What is Terumo's approach to digital health?
Historically a hardware-focused device manufacturer, Terumo has shifted toward connected therapeutic devices that layer software monitoring onto its installed base of infusion pumps, blood-monitoring systems, and cardiovascular implants. The March 2024 consolidation of digital-health units under a single division formalized this strategy, using the HealthSense platform as an architecture to add remote-monitoring capabilities to the broader product portfolio.
How does Terumo's Japanese regulatory expertise factor into its investment model?
Japan's PMDA regulatory pathway for medical devices requires specific clinical data and local quality-system compliance that foreign device companies often struggle to navigate independently. Terumo's in-house regulatory team provides portfolio companies with a pre-built PMDA submission framework, potentially accelerating Japan-market approvals by months relative to competitors entering without a local partner. This regulatory moat forms a core part of Terumo's value proposition to investee firms.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: